13F Holdings
中文EN

ATYR aTYR PHARMA INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1339970 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-19.1%
TTM net income YoY-15.8%
TTM EPS YoY7.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-40,856.3%
Net margin-39,009.5%
FCF margin-32,664.7%
EBITDA margin-40,506.8%

Returns

ROE-107.8%
ROA-78.1%
ROIC (approx.)-106.0%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets27.6%
Debt / equity0.00x
Current ratio5.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-12.8%
Payout ratio—
Capex / revenue40.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$190,000$235,000$353,000$10.39M$0
R&D expense$60.22M$54.37M$42.29M$42.81M$23.26M
SG&A expense$17.60M$13.78M$12.98M$13.98M$10.75M
Operating income-$77.63M-$67.91M-$54.92M-$46.40M-$34.02M
Pretax income-$74.12M-$64.02M-$50.40M-$45.34M-$33.77M
Income tax$0$0$0$0$0
Net income-$74.12M-$64.02M-$50.39M-$45.34M-$33.77M
EBITDA-$76.96M-$67.21M-$54.33M-$46.17M-$33.54M
EPS (basic)-0.80-0.86-0.94-1.60-1.77
EPS (diluted)-0.80-0.86-0.94-1.60-1.77
Weighted avg. shares (diluted)92.99M74.26M53.61M28.42M19.08M
Balance sheet
Cash & equivalents$10.74M$11.05M$22.54M$9.98M$2.34M
Short-term investments$67.94M$61.07M$75.62M$56.16M$105.58M
Current assets$80.24M$81.95M$102.99M$80.87M$113.57M
PP&E, net$4.26M$4.85M$5.53M$3.06M$543,000
Total assets$93.00M$96.83M$120.65M$95.79M$115.54M
Current liabilities$15.15M$14.97M$16.42M$13.86M$6.01M
Total liabilities$25.71M$27.00M$30.18M$24.50M$6.41M
Shareholders' equity$67.48M$70.02M$90.66M$71.46M$109.30M
Shares outstanding2.45M84.04M63.29M29.50M27.79M
Cash flow statement
Operating cash flow-$61.99M-$69.12M-$33.22M-$41.89M-$33.08M
Capital expenditure$77,000$65,000$4.21M$1.64M$192,000
Free cash flow-$62.06M-$69.18M-$37.44M-$43.53M-$33.27M
Investing cash flow-$5.05M$17.23M-$20.13M$47.24M-$91.57M
Financing cash flow$66.01M$39.86M$66.23M$5.45M$110.03M
Depreciation & amortization$664,000$708,000$592,000$232,000$475,000
Stock-based compensation$5.00M$2.99M$2.60M$2.15M$1.61M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.